Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sodium carboxymethylcellulose is a semi-synthetic, water-soluble polymer derived from cellulose. It is widely used as an ophthalmic lubricant (artificial tears) for the symptomatic relief of dry eyes and ocular irritation due to wind or sun exposure. In pharmaceutical manufacturing, it serves as an excipient—acting as a binder and disintegrant in tablets, a thickener and stabilizer in liquid formulations, and a film-former in topical preparations. Its mechanism of action in ophthalmology involves binding to corneal epithelial cells via glucopyranose subunits interacting with glucose transporters (GLUT1), promoting corneal wound healing by facilitating cell attachment and migration. Sodium carboxymethylcellulose is generally regarded as safe (GRAS) for use in food products as a thickener or stabilizer[1][2][4][5][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sodium carboxymethylcellulose.